Due to heightened risk for thromboembolic complications, nonvalvular atrial fi brillation (NVAF) presents an absolute indication for long-term oral anticoagulation therapy. Th is was an observational, analytical, randomised, one-year clinical study, conducted in the Blood Transfusion Institute Sarajevo, Bosnia & Herzegovina. Th e aim of this study was to present the oral anticoagulation treatment in terms of International normalised ratio (INR) monitoring and warfarin/acenocoumarol dose titration in  patients with NVAF. INR values, the doses of warfarin and acenocoumarol, as well as the tendency and adequacy of their changes were monitored. Percentages of the therapeutic INR values were , and ,, subtherapeutic , and ,, and supratherapeutic , and , for the warfarin and acenocoumarol treatment, respectively. Th e average total weekly doses (TWD) which most frequently achieved the therapeutic INR values were ,±, mg and ,±, mg, for warfarin and acenocoumarol, respectively. Th e dose changes with the INR values , or lower/, or higher were omitted in , and ,, and with the INR values ,-, were noted in , and , of all the check-up visits in the warfarin and acenocoumarol group, respectively. Th e annual dose changes were noted in , and ,, and the daily dose changes in , and , of all the check-up visits of warfarin and acenocoumarol group, respectively. We can conclude that the management of the oral anticoagulation treatment in our country is in accordance with the relevant recommendations, but with the present tendency toward underdosing and unnecessary frequent dose changing.
Introduction
Vitamin K antagonists, warfarin and acenocoumarol are oral anticoagulant drugs currently available for the long-term prevention of stroke in patients with nonvalvular atrial fibrillation (NVAF). In due to heightened risk for thromboembolic complications, these patients suff er from stroke , times more often than people without arrhythmia () . Numerous studies have shown that warfarin and acenocoumarol are underused drugs in patients with atrial fi brillation (, ) . Th e latest recommendations for wide use of oral anticoagulation drugs for patients with NVAF, based on the control of INR values, have been published by American College of Chest Physicians (ACCP, th Edition) (, , ) . The anticoagulation effects are measured by the prothrombin time (PT), which is according to the recommendation of the World Health Organization stated as International normalised ratio (INR) () . Th e target INR range (,-,) is achieved in only - of patients () . Th e dosing is regularly adjusted to the age of the patient, gender, clinical variables which influence mechanism and metabolism of the drug, and the individual risk of haemorrhage and thrombosis () . According to the latest studies, two genes mutation-gene for cytochrome P (CYPC and CYPF) and gene for vitamin K epoxide reductase complex (VKORC) are responsible for one third of all variations of the total weekly doses (TWD) of warfarin (, , , ) . Management of the anticoagulation treatment is very complex due to a number of issues such as () : the narrow therapeutic index, the tendency toward unpredictable INR fluctuations, the significant interindividual and intraindividual variations in the patients' response, the regular obligatory laboratory testing of INR and the dose adjustments. Th erefore, the aim of this study was to present the oral anticoagulation treatment in terms of the INR monitoring and warfarin/ acenocoumarol dose titration in patients with NVAF. Th e analysis of the relevant databases has not provided any information with regards to whether this kind of problem has ever been addressed and researched in our country. This is the first study of the management of the oral anticoagulation treatment in B&H.
Patients and Methods

Study design
Th is was an observational, analytical, randomised, bidirectional (prospective and retrospective), one-year clinical study, conducted in the Blood Transfusion Institute Sarajevo, Bosnia & Herzegovina. Study was conducted according to the GCP (Good Clinical Practise), GLP (Good Laboratory Practise) and local ethical principles. All patients who were using warfarin/acenocoumarol therapy and were monitored by medical team in this Institute were eligible. The patient inclusion criteria were, as follows: the age of -, diagnosed NVAF, CHADS index score ≥ () , the planned long-term treatment with warfarin/acenocoumarol started at least  months prior to the observational period and a signed informed consent. Diagnose of NVAF, indication for oral anticoagulant treatment and target INR range were determined in competent specialised institutions and adequately documented by medical records. In order not to be biased, included patients were separated by the method of centralized computer randomisation into two parallel groups of  patients. Groups were homogenized according to the anticoagulation therapy (warfarin/acenocoumarol) as well as the gender and age. Th e duration of the observational period was  months. Retrospectively, the previous  months from the day of screening were observed, and prospectively, the following six months. Th e INR values, the doses of warfarin and acenocoumarol, as well as the tendency and adequacy of their changes were monitored. Th e control visits were on a monthly basis, or even more frequently, whenever necessary.
Data collection and analysis
Anamnestic data collected at screening visit (age, gender, weight, height, CHADS index score, comorbodities, smoke and alcohol use) are gathered in a study sheet. Data gathered in the especially designed Patient's Diary were as follows: dates of measurements, INR values and the daily warfarin/acenocoumarol doses, collected via retrospective chart review of monthly patient organisers (retrospective data for  months prior to enrolment) and prospectively for the following six months. In prospective part of study, additional data (the adherence to the treatment, temporary or permanent interruption of the treatment, and the use of concomitant drugs) were assessed and collected. Th e data were collected in the Microsoft Office Excel database and statistically analysed by MedCalc for Windows program, Version ... (MedCalc Software, Mariakerke, Belgium). Descriptive statistical analysis presented as arithmetic mean value and standard deviation (SD) was performed. Quality of treatment was expressed as percentages of therapeutic, subtherapeutic and supratherapeutic INR values, and average doses were expressed as arithmetic mean value ± SD.
INR measurement
In order to measure INR values, the blood samples were taken in the morning, by the venepuncture of the cubital vein. The blood has been taken into a , sodium citrate test-tube (Vacutainer, Becton Dickinson, Great Britain). All INR measurements were conducted in the same laboratory, on the fresh plasma obtained from blood samples centrifuged at room temperature at  g for  minutes (Laboratory centrifuge CEN-TRIC A, Slovenia). The automatic haemostasis scanner were used (CD-X, Switzerland), with liquid calcium rabbit thromboplastin (DiaPlastin-E, ISI=,). Th e measurement of INR values was done according to the following formulae: INR = (PT ratio) ISI () 
Discussion
Homogenisation of both therapeutic groups in our study, based on the number of patients, gender and age, contributed to the reliability of our results. The average INR values in the therapeutic groups were within the target range (,-,), but with the clear tendency toward low therapeutic limit (,±, and ,±,).
Analysis of overall quality of treatment showed that portion of therapeutic INR values in this study was , and , in warfarin and acenocoumarol group, respectively. Similar data has been published with the therapeutic INR values achieved in - of all measurements in specialized anticoagulation clinics ( (, ) . Th e daily doses of warfarin to achieve the therapeutic INR values are usually from , to  mg (). Analysis in this study showed that the average daily doses of warfarin (,±, mg) and acenocoumarol (,±, mg) were in recommended range but with the tendency toward low therapeutic dose level. Taking into account that the average INR values in the both therapeutic groups were within the therapeutic range, with more than a half therapeutic INR values, we can suggest that majority of our patients achieved the therapeutic INR values with low warfarin doses. Th is warfarin doses were signifi cantly lower and acenocoumarol doses were slightly higher compared to the SPORTIF-III study (,±, mg of warfarin, and ,±, mg of acenocoumarol) () . Since the average ages of our patients were  years in warfarin and  years in acenocoumarol group, fi ndings confi rmed from previously published literature (, ) that elderly patients need smaller TWDs of these drugs, can be taken as a relevant explanation for the occurrence mentioned above. Due to the homogenisation of the group and the subsequent elimination of other signifi cantly important infl uences, we can also conclude that the other reasons for low dose levels of warfarin in this study can be either CYPC polymorphism with genetically higher sensitivity to warfarin or exposition to interacting co-medications which are known to increase the anticoagulation eff ects. Approximately - of patients who have  or  polymorph allele for CYPC, can achieve the therapeutic INR value with the dosing of , mg/day () . Th e analysis of the average INR values and related average TWDs of warfarin has shown, that during the winter, the maintenance of the stable INR values requires higher doses of warfarin ( Figure ) . It has been mentioned in earlier medical literature as the seasonal variations in the oral anticoagulation treatment (). We did not notice any eff ects of the seasonal variations in the acenocoumarol treatment ( Figure ) . Th e ratio of average weekly doses of warfarin and acenocoumarol which needs to be taken into consideration when thinking about a possible change of treatments, in our study was ,. It means that approximately , times higher warfarin dose is needed in the same patient than those of acenocoumarol. It is signifi cantly lower transition factor compared to , and ,, results from the other studies (, ) .
Th e doses should be adjusted so that the total dose from the previous week is increased or decreased for - () . Th e results of our study have shown that, in order to move from the subtherapeutic (,-,) to therapeutic (,-,) INR values, a similar increase of , of the TWD of warfarin is required. Expressed in milligrams, the change mentioned above was around , mg of warfarin. Th e most of INR values (,) used in the evaluation of the described necessary changes of warfarin dosing were ,-, INR values. Based on the same data concerning acenocoumarol, and according to the results of this study, in order to move from the subtherapeutical to therapeutical INR values, the weekly dose of acenocoumarol should be increased for ,, which in this study was around , mg. We examined the methods of the dosing titration in this study taking into consideration the study conducted by Rose et al. () and their suggestion that dosing should ideally be changed only in cases with the INR values , or lower/, or higher. These authors suggest that in that case  of INR values will be possible to achieve within the therapeutic range. Figure ) , can be the reason for the lower INR quality noted in our study. According to numerous other studies, the therapy with oral anticoagulation drugs is often suboptimal, usually due to the doctors' fear of haemorrhage and them being too cautious when it comes to the dosing (, , ) . Th e evaluation of the oral anticoagulation treatment in our study has clearly shown the tendency toward frequent dose changes, especially frequent daily dose changes, to underdose and to keep the INR values in low therapeutical levels.
Conclusion
Monitoring of the oral anticoagulation treatment in this study is in accordance with the relevant ACCP recommendations, but with the present tendency toward underdosing. As expected, this study suggests that the way of warfarin/ acenocoumarol dosing titration may have signifi cant infl uence on quality of oral anticoagulation treatment. Frequent underdosing, inadequate dose titration in terms of each omitted and unnecessary annual and daily dose changes in patients with NVAF can be the main reason for frequent suboptimal INR values. In order to maintain better INR monitoring we hope that, in near future, we will encounter models such as the computerised dosing and anticoagulation self-management in B&H.
